Quetiapine treatment in early psychosis: 1 year outcomes
Identifieur interne : 000262 ( Istex/Corpus ); précédent : 000261; suivant : 000263Quetiapine treatment in early psychosis: 1 year outcomes
Auteurs : L. Kopala ; H. Woodley ; L. A. Campbell ; J. Gallant ; Q. Rui ; H. Milliken ; D. WhitehornSource :
- Acta Psychiatrica Scandinavica [ 0001-690X ] ; 2002-09.
Abstract
Objective To determine clinical response, dosing and adverse events associated with quetiapine treatment in early psychosis.
Url:
DOI: 10.1034/j.1600-0447.106.s413.1_12.x
Links to Exploration step
ISTEX:0FF823DD25A3ADED2D36B9D5592A032B04E0425CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quetiapine treatment in early psychosis: 1 year outcomes</title><author><name sortKey="Kopala, L" sort="Kopala, L" uniqKey="Kopala L" first="L." last="Kopala">L. Kopala</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Woodley, H" sort="Woodley, H" uniqKey="Woodley H" first="H." last="Woodley">H. Woodley</name><affiliation><mods:affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</mods:affiliation></affiliation></author><author><name sortKey="Campbell, L A" sort="Campbell, L A" uniqKey="Campbell L" first="L. A." last="Campbell">L. A. Campbell</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Gallant, J" sort="Gallant, J" uniqKey="Gallant J" first="J." last="Gallant">J. Gallant</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Rui, Q" sort="Rui, Q" uniqKey="Rui Q" first="Q." last="Rui">Q. Rui</name><affiliation><mods:affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</mods:affiliation></affiliation></author><author><name sortKey="Milliken, H" sort="Milliken, H" uniqKey="Milliken H" first="H." last="Milliken">H. Milliken</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Whitehorn, D" sort="Whitehorn, D" uniqKey="Whitehorn D" first="D." last="Whitehorn">D. Whitehorn</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0FF823DD25A3ADED2D36B9D5592A032B04E0425C</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1034/j.1600-0447.106.s413.1_12.x</idno><idno type="url">https://api.istex.fr/document/0FF823DD25A3ADED2D36B9D5592A032B04E0425C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000262</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000262</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quetiapine treatment in early psychosis: 1 year outcomes</title><author><name sortKey="Kopala, L" sort="Kopala, L" uniqKey="Kopala L" first="L." last="Kopala">L. Kopala</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Woodley, H" sort="Woodley, H" uniqKey="Woodley H" first="H." last="Woodley">H. Woodley</name><affiliation><mods:affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</mods:affiliation></affiliation></author><author><name sortKey="Campbell, L A" sort="Campbell, L A" uniqKey="Campbell L" first="L. A." last="Campbell">L. A. Campbell</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Gallant, J" sort="Gallant, J" uniqKey="Gallant J" first="J." last="Gallant">J. Gallant</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Rui, Q" sort="Rui, Q" uniqKey="Rui Q" first="Q." last="Rui">Q. Rui</name><affiliation><mods:affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</mods:affiliation></affiliation></author><author><name sortKey="Milliken, H" sort="Milliken, H" uniqKey="Milliken H" first="H." last="Milliken">H. Milliken</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author><author><name sortKey="Whitehorn, D" sort="Whitehorn, D" uniqKey="Whitehorn D" first="D." last="Whitehorn">D. Whitehorn</name><affiliation><mods:affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Psychiatrica Scandinavica</title><idno type="ISSN">0001-690X</idno><idno type="eISSN">1600-0447</idno><imprint><publisher>Blackwell publishers</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="volume">106</biblScope><biblScope unit="supplement">s413</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="106">106</biblScope></imprint><idno type="ISSN">0001-690X</idno></series><idno type="istex">0FF823DD25A3ADED2D36B9D5592A032B04E0425C</idno><idno type="DOI">10.1034/j.1600-0447.106.s413.1_12.x</idno><idno type="ArticleID">ACPSPO119_12</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-690X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objective To determine clinical response, dosing and adverse events associated with quetiapine treatment in early psychosis.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>L. Kopala</name><affiliations><json:string>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</json:string></affiliations></json:item><json:item><name>H. Woodley</name><affiliations><json:string>Nova Scotia Early Psychosis Program, Dartmouth, Canada</json:string></affiliations></json:item><json:item><name>L. A. Campbell</name><affiliations><json:string>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</json:string></affiliations></json:item><json:item><name>J. Gallant</name><affiliations><json:string>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</json:string></affiliations></json:item><json:item><name>Q. Rui</name><affiliations><json:string>Nova Scotia Early Psychosis Program, Dartmouth, Canada</json:string></affiliations></json:item><json:item><name>H. Milliken</name><affiliations><json:string>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</json:string></affiliations></json:item><json:item><name>D. Whitehorn</name><affiliations><json:string>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</json:string></affiliations></json:item></author><articleId><json:string>ACPSPO119_12</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><qualityIndicators><score>5.192</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595 x 791 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractCharCount>125</abstractCharCount><pdfWordCount>31301</pdfWordCount><pdfCharCount>205599</pdfCharCount><pdfPageCount>38</pdfPageCount><abstractWordCount>16</abstractWordCount></qualityIndicators><title>Quetiapine treatment in early psychosis: 1 year outcomes</title><genre><json:string>abstract</json:string></genre><host><volume>106</volume><publisherId><json:string>ACPS</json:string></publisherId><pages><last>106</last><first>69</first></pages><issn><json:string>0001-690X</json:string></issn><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0447</json:string></eissn><title>Acta Psychiatrica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0447</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>psychiatry</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>psychiatry</json:string></scienceMetrix></categories><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1034/j.1600-0447.106.s413.1_12.x</json:string></doi><id>0FF823DD25A3ADED2D36B9D5592A032B04E0425C</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/0FF823DD25A3ADED2D36B9D5592A032B04E0425C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/0FF823DD25A3ADED2D36B9D5592A032B04E0425C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0FF823DD25A3ADED2D36B9D5592A032B04E0425C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Quetiapine treatment in early psychosis: 1 year outcomes</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell publishers</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Quetiapine treatment in early psychosis: 1 year outcomes</title><author xml:id="author-1"><persName><forename type="first">L.</forename><surname>Kopala</surname></persName><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation></author><author xml:id="author-2"><persName><forename type="first">H.</forename><surname>Woodley</surname></persName><affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</affiliation></author><author xml:id="author-3"><persName><forename type="first">L. A.</forename><surname>Campbell</surname></persName><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation></author><author xml:id="author-4"><persName><forename type="first">J.</forename><surname>Gallant</surname></persName><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation></author><author xml:id="author-5"><persName><forename type="first">Q.</forename><surname>Rui</surname></persName><affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</affiliation></author><author xml:id="author-6"><persName><forename type="first">H.</forename><surname>Milliken</surname></persName><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation></author><author xml:id="author-7"><persName><forename type="first">D.</forename><surname>Whitehorn</surname></persName><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation></author></analytic><monogr><title level="j">Acta Psychiatrica Scandinavica</title><idno type="pISSN">0001-690X</idno><idno type="eISSN">1600-0447</idno><idno type="DOI">10.1111/(ISSN)1600-0447</idno><imprint><publisher>Blackwell publishers</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-09"></date><biblScope unit="volume">106</biblScope><biblScope unit="supplement">s413</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="106">106</biblScope></imprint></monogr><idno type="istex">0FF823DD25A3ADED2D36B9D5592A032B04E0425C</idno><idno type="DOI">10.1034/j.1600-0447.106.s413.1_12.x</idno><idno type="ArticleID">ACPSPO119_12</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Objective To determine clinical response, dosing and adverse events associated with quetiapine treatment in early psychosis.</p></abstract><abstract><p>Method 40 Patients (33 men; 7 women; mean age 23.75) with schizophrenia spectrum disorders and less than 6 months previous exposure to antipsychotic treatment, entered an open label, 2 years, flexible dose trial and were assessed with PANSS, CGI, GAF, SOFAS, ESRS, BMI and ocular exams at baseline and 6 month intervals thereafter.</p></abstract><abstract><p>Results Among 30 patients who enrolled >1 years ago, 19 (63%) completed 1‐year assessment. Dropouts were due to insufficient clinical response (13%), nonadherence (13%) and personal choice (10%). At 1 year, significant improvement was observed on the PANSS, CGI, GAF and SOFAS. Mean dose was 559 (±207) mg/day. No drug induced EPS was noted and EPS present at baseline was reduced. Mean change in BMI was 17% (±22). No ocular changes were observed.</p></abstract><abstract><p>Conclusions Quetiapine was well tolerated. Clinical response was similar to that achieved with other second generation antipsychotic agents in the same early psychosis programme.</p></abstract></profileDesc><revisionDesc><change when="2002-09">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-12-13">References added</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-02-9">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/0FF823DD25A3ADED2D36B9D5592A032B04E0425C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell publishers</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0447</doi><issn type="print">0001-690X</issn><issn type="electronic">1600-0447</issn><idGroup><id type="product" value="ACPS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA PSYCHIATRICA SCANDINAVICA">Acta Psychiatrica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="09000"><doi origin="wiley">10.1111/acp.2002.106.issue-s413</doi><numberingGroup><numbering type="journalVolume" number="106">106</numbering><numbering type="supplement">s413</numbering></numberingGroup><coverDate startDate="2002-09">September 2002</coverDate></publicationMeta><publicationMeta level="unit" type="abstract" position="0006900" status="forIssue"><doi origin="wiley">10.1034/j.1600-0447.106.s413.1_12.x</doi><idGroup><id type="unit" value="ACPSPO119_12"></id></idGroup><titleGroup><title type="tocHeading1">Posters</title></titleGroup><eventGroup><event type="firstOnline" date="2008-07-18"></event><event type="publishedOnlineFinalForm" date="2008-07-18"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:Header result:Header" date="2010-03-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-01"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="69">69</numbering><numbering type="pageLast" number="106">106</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:ACPS.ACPSpo119_12.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="0"></count><count type="wordTotal" number="0"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Quetiapine treatment in early psychosis: 1 year outcomes</title><title type="shortAuthors">Thursday, 26–Saturday, 28 September 2002</title><title type="short">3rd International Conference on Early Psychosis</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a11-29"><personName><givenNames>L.</givenNames><familyName>Kopala</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a11-30"><personName><givenNames>H.</givenNames><familyName>Woodley</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a11-29"><personName><givenNames>L. A.</givenNames><familyName>Campbell</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a11-29"><personName><givenNames>J.</givenNames><familyName>Gallant</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a11-30"><personName><givenNames>Q.</givenNames><familyName>Rui</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a11-29"><personName><givenNames>H.</givenNames><familyName>Milliken</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a11-29"><personName><givenNames>D.</givenNames><familyName>Whitehorn</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a11-29" countryCode="CA"><unparsedAffiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</unparsedAffiliation></affiliation><affiliation xml:id="a11-30" countryCode="CA"><unparsedAffiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Objective </b> To determine clinical response, dosing and adverse events associated with quetiapine treatment in early psychosis.</p><p><b>Method </b> 40 Patients (33 men; 7 women; mean age 23.75) with schizophrenia spectrum disorders and less than 6 months previous exposure to antipsychotic treatment, entered an open label, 2 years, flexible dose trial and were assessed with PANSS, CGI, GAF, SOFAS, ESRS, BMI and ocular exams at baseline and 6 month intervals thereafter.</p><p><b>Results </b> Among 30 patients who enrolled >1 years ago, 19 (63%) completed 1‐year assessment. Dropouts were due to insufficient clinical response (13%), nonadherence (13%) and personal choice (10%). At 1 year, significant improvement was observed on the PANSS, CGI, GAF and SOFAS. Mean dose was 559 (±207) mg/day. No drug induced EPS was noted and EPS present at baseline was reduced. Mean change in BMI was 17% (±22). No ocular changes were observed.</p><p><b>Conclusions </b> Quetiapine was well tolerated. Clinical response was similar to that achieved with other second generation antipsychotic agents in the same early psychosis programme.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Quetiapine treatment in early psychosis: 1 year outcomes</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>3rd International Conference on Early Psychosis</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Quetiapine treatment in early psychosis: 1 year outcomes</title></titleInfo><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Kopala</namePart><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Woodley</namePart><affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L. A.</namePart><namePart type="family">Campbell</namePart><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Gallant</namePart><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Rui</namePart><affiliation>Nova Scotia Early Psychosis Program, Dartmouth, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Milliken</namePart><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Whitehorn</namePart><affiliation>Dalhousie University, Department of Psychiatry, Dartmouth, Canada,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract"></genre><originInfo><publisher>Blackwell publishers</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2002-09</dateIssued><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Objective To determine clinical response, dosing and adverse events associated with quetiapine treatment in early psychosis.</abstract><abstract>Method 40 Patients (33 men; 7 women; mean age 23.75) with schizophrenia spectrum disorders and less than 6 months previous exposure to antipsychotic treatment, entered an open label, 2 years, flexible dose trial and were assessed with PANSS, CGI, GAF, SOFAS, ESRS, BMI and ocular exams at baseline and 6 month intervals thereafter.</abstract><abstract>Results Among 30 patients who enrolled >1 years ago, 19 (63%) completed 1‐year assessment. Dropouts were due to insufficient clinical response (13%), nonadherence (13%) and personal choice (10%). At 1 year, significant improvement was observed on the PANSS, CGI, GAF and SOFAS. Mean dose was 559 (±207) mg/day. No drug induced EPS was noted and EPS present at baseline was reduced. Mean change in BMI was 17% (±22). No ocular changes were observed.</abstract><abstract>Conclusions Quetiapine was well tolerated. Clinical response was similar to that achieved with other second generation antipsychotic agents in the same early psychosis programme.</abstract><relatedItem type="host"><titleInfo><title>Acta Psychiatrica Scandinavica</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0001-690X</identifier><identifier type="eISSN">1600-0447</identifier><identifier type="DOI">10.1111/(ISSN)1600-0447</identifier><identifier type="PublisherID">ACPS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s413</number></detail><extent unit="pages"><start>69</start><end>106</end></extent></part></relatedItem><identifier type="istex">0FF823DD25A3ADED2D36B9D5592A032B04E0425C</identifier><identifier type="DOI">10.1034/j.1600-0447.106.s413.1_12.x</identifier><identifier type="ArticleID">ACPSPO119_12</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell publishers</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000262 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000262 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0FF823DD25A3ADED2D36B9D5592A032B04E0425C
|texte= Quetiapine treatment in early psychosis: 1 year outcomes
}}
| This area was generated with Dilib version V0.6.29. |  |